ArticleJournal of the American Heart Association2022
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.
- Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety.International journal of molecular sciences · 2025Pooled it
- Baseline modern medical management in the BEST-CLI trial.Journal of vascular surgery · 2023Trial
- Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- SGLT2i use and fracture risk compared with DPP4i in patients with T2DM.Journal of diabetes investigation · 2026Article
- Temporal Trends and Disparities in Type 2 Diabetes Mellitus and Congestive Heart Failure Mortality in the United States From 1999-2020: A CDC WONDER Analysis.Health science reports · 2026Article
- Glycemic control and clinical outcomes in patients with diabetes and atrial fibrillation: a nationwide cohort study.Acta diabetologica · 2026Article
- Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes.Clinical pharmacology and therapeutics · 2026Article
- Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study.Diabetes, obesity & metabolism · 2026Article
- Sodium-glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real-world cohort study.Epilepsia · 2026Article
- Finerenone Prescriptions in the United States (2021-2024) by Physician Specialty: Analysis of Use and Potential in the Cardiovascular-Kidney-Metabolic Space.Journal of the American Heart Association · 2026Article
- Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study.BMC nephrology · 2026Article
- Missing Opportunity for Nephroprotective Therapy in Patients With Non-Dialysis CKD Under Stable Nephrology Care.Kidney international reports · 2026Article
- Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis.Neurology international · 2026Article
- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Transcatheter Aortic Valve Replacement: A Real-World Propensity-Matched Analysis.Structural heart : the journal of the Heart Team · 2026Article
- Comparative Clinical Analysis of DPP-4 inhibitors and SGLT2 Inhibitors: A Real-World Switch Study.Journal of obesity & metabolic syndrome · 2026Article
- Impact of herpes zoster and post-zoster SGLT2 inhibitors initiation on cardiorenal outcomes in type 2 diabetes mellitus.BMC endocrine disorders · 2026Article
- Bone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2).Calcified tissue international · 2026Article
- Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors.European journal of clinical pharmacology · 2026Review
- Trends in the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists among ischemic stroke patients.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Gliflozins in Practice: Real-Life Use of Dapagliflozin and Empagliflozin in HFrEF Versus Clinical Trial Data.Diagnostics (Basel, Switzerland) · 2026Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) mitigate cardiovascular risk in individuals with type 2 diabetes, but most eligible patients do not receive them. We characterized temporal trends in SGLT2i and GLP-1RA use by cardiologists compared with other groups of clinicians. Methods and Results We conducted a descriptive analysis of serial, cross-sectional data derived from IQVIA's National Prescription Audit, a comprehensive audit capturing ≈90% of US retail prescription dispensing and projected to population-level data, to estimate monthly SGLT2is and GLP-1RAs dispensed from January 2015 to December 2020, stratified by prescriber specialty and molecule. We also used the American Medical Association's Physician Masterfile to calculate average annual SGLT2is and GLP-1RAs dispensed per physician. Between January 2015 and December 2020, a total of 63.2 million SGLT2i and 63.4 million GLP-1RA prescriptions were dispensed in the United States. Monthly prescriptions from cardiologists increased 12-fold for SGLT2is (from 2228 to 25 815) and 4-fold for GLP-1RAs (from 1927 to 6981). Nonetheless, cardiologists represented only 1.5% of SGLT2i prescriptions and 0.4% of GLP-1RA prescriptions in 2020, while total use was predominated by primary care physicians/internists (57% of 2020 SGLT2is and 52% of GLP-1RAs). Endocrinologists led in terms of prescriptions dispensed per physician in 2020 (272 SGLT2is and 405 GLP-1RAs). Cardiologists, but not noncardiologists, increasingly used SGLT2is over GLP-1RAs, with accelerated uptake of empagliflozin and dapagliflozin coinciding with their landmark cardiovascular outcomes trials and subsequent US Food and Drug Administration label expansions. Conclusions While use of SGLT2is and GLP-1RAs by cardiologists in the United States increased substantially over a 6-year period, cardiologists still account for a very small proportion of all use, contributing to marked undertreatment of individuals with type 2 diabetes at high cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.